A screaming summer buy... but when-?
Outlook Therapeutics, Inc. (OTLK) @$1.15
NasdaqCM - NasdaqCM Real Time Price.
1.1500+0.0200(+1.77%)
$1,000 Turns into $5,000-$7,000
Guggenheim starts Outlook Therapeutics at Buy on Lytenava opportunity 04/03 OTLK As previously reported, Guggenheim analyst Eddie Hickman initiated coverage of Outlook Therapeutics with a Buy rating and $5 price target. The anti-VEGF market is currently dominated by several blockbuster branded products and an emerging biosimilar line-up, but up to 40% of anti-VEGF injections are done with off-label bevacizumab purchased from compounding pharmacies, which is something not officially approved by the FDA, the firm tells investors. Outlook Therapeutics has developed an on-label ophthalmic formulation of bevacizumab to potentially replace the reformulated version and Guggenheim believes "the Street is overlooking the significant market opportunity that could emerge" if Lytenava is approved and compounding pharmacies are forced to cease production of the off-label formulation. The firm notes that the Lytenava PDUFA date is coming up on August 29.